As we observe Endometriosis Awareness Month in March, let us take a look at 7 biotech companies advancing promising ...

Similar is the case for other big players—Gland Pharma (54 percent), Aurobindo (48), Zydus (47 ... “This system ensures that ...

The first RIPTAC has just hit the clinic. Learn about this new technology that is being developed by Halda Therapeutics.

Novartis paid Takeda $3.4 billion for its FDA-approved dry eye drug Xiidra during the Japanese pharma’s merger with ... eye disease caused by Meibomian gland dysfunction (MGD) reaching ...

The project will involve analysing trends and patterns in LTCs to identify patients who would most benefit from tele-health, tele-care and tele-medicine ... of a trend for pharma companies ...

Gland Pharma Ltd share price was down by -0.67% from the previous closing price of ₹1,634.00. Who are peers of Gland Pharma Ltd? The peers of Gland Pharma Ltd are Sun Pharmaceutical Industries ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Researchers have uncovered a promising therapeutic target for adenoid cystic carcinoma (ACC), a rare cancer of the salivary ...

Gland Pharma shares jumped 5.8 percent in the morning deals, logging an intraday high at ₹1,664.4 per share. The stock advanced after multiple bulk deals. Around 10:50 AM, Gland Pharma share price was ...

The German firm licensed a PRMT5 inhibitor that’s now in Phase 1 testing. Elsewhere, GSK is testing an intriguing hypothesis and Novo fine tuned its Wegovy cash-pay program.